Pediatric Respiratory Failure Medication
- Author: Shelley C Springer, MD, MBA, MSc, JD, FAAP; Chief Editor: Timothy E Corden, MD more...
Medication Summary
The use of medications in the treatment of respiratory failure depends on the underlying disorder. For example, corticosteroids and beta-agonist medications treat an asthma exacerbation, whereas antibiotics treat bacterial pneumonia. Patients with pulmonary edema from myocardial dysfunction improve with diuretics and inotropic support.
Pulmonary Vasodilators
Class Summary
Inhaled nitric oxide (NO) is a pulmonary vasodilator indicated to treat pulmonary hypertension. NO is also being studied for severe hypoxemia in acute respiratory distress syndrome (ARDS).
Nitric oxide, inhaled (INOmax)
NO is produced endogenously from the action of the enzyme NO synthetase on arginine. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine monophosphate (cGMP), which then leads to vasodilation. When inhaled, NO decreases pulmonary vascular resistance and improves lung blood flow.
Lung Surfactants
Class Summary
Exogenous surfactant can be helpful in the treatment of airspace disease. After inhalation, surface tension is reduced and alveoli are stabilized, decreasing the work of breathing and increasing lung compliance. These drugs are indicated for the prevention and treatment of neonatal RDS. They are also being investigated for the treatment of hypoxemia secondary to ARDS.
Calfactant (Infasurf)
This is a natural bovine calf lung extract containing phospholipids, fatty acids, and surfactant-associated proteins B (260 mcg/mL) and C (390 mcg/mL). Surfactant is an endogenous complex of lipids and proteins that lines alveolar walls and promotes alveolar stability by reducing surface tension. Relative surfactant deficiency is variably present in many lung diseases.
Poractant alfa (Curosurf)
Poractant alfa lines the alveolar walls and promotes alveolar stability against collapse by reducing surface tension at the air-liquid interface of the alveoli.
Institute for Clinical Systems Improvement (ICSI). Diagnosis and treatment of respiratory illness in children and adults. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2008 Jan.
de Klerk A. Humidified high-flow nasal cannula: is it the new and improved CPAP?. Adv Neonatal Care. Apr 2008;8(2):98-106. [Medline].
Ralstonia associated with Vapotherm oxygen delivery device--United States, 2005. MMWR Morb Mortal Wkly Rep. Oct 21 2005;54(41):1052-3. [Medline].
Spence KL, Murphy D, Kilian C, McGonigle R, Kilani RA. High-flow nasal cannula as a device to provide continuous positive airway pressure in infants. J Perinatol. Dec 2007;27(12):772-5. [Medline].
Campbell DM, Shah PS, Shah V, Kelly EN. Nasal continuous positive airway pressure from high flow cannula versus Infant Flow for Preterm infants. J Perinatol. Sep 2006;26(9):546-9. [Medline].
Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med. Jun 10 2004;350(24):2452-60. [Medline].
Habashi NM. Other approaches to open-lung ventilation: airway pressure release ventilation. Crit Care Med. Mar 2005;33(3 Suppl):S228-40. [Medline].
Curley MA, Hibberd PL, Fineman LD, et al. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial. JAMA. Jul 13 2005;294(2):229-37. [Medline].
Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. Jan 26 2005;293(4):470-6. [Medline]. [Full Text].
Conrad SA, Rycus PT, Dalton H. Extracorporeal Life Support Registry Report 2004. ASAIO J. Jan-Feb 2005;51(1):4-10. [Medline].
Children's Healthcare of Atlanta. Available at http://www.lchoa.org/childrens-hospital-services/critical-care/ECMO-center/Volumes-and-Outcomes. Accessed 14 January, 2012.
Haines NM, Rycus PT, Zwischenberger JB, Bartlett RH, Undar A. Extracorporeal Life Support Registry Report 2008: neonatal and pediatric cardiac cases. ASAIO J. Jan-Feb 2009;55(1):111-6. [Medline].
Extracorporeal Life Support Organization. H1N1 ECLS Registry, Statistics from the H1N1 Registry (as of May 28, 2010). Available at http://www.elso.med.umich.edu/H1N1Registry.html.
Gadek JE, DeMichele SJ, Karlstad MD, Pacht ER, Donahoe M, Albertson TE, et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med. Aug 1999;27(8):1409-20. [Medline].
Singer P, Shapiro H. Enteral omega-3 in acute respiratory distress syndrome. Curr Opin Clin Nutr Metab Care. Mar 2009;12(2):123-8. [Medline].
| Year | CHA (US) | International |
| 2005 | 58% | 54% |
| 2006 | 47% | 53% |
| 2007 | 71% | 56% |
| 2008 | 57% | 54% |
| 2009 | 75% | 55% |
| Diagnosis | CHA (US) | International |
| Bacterial pneumonia | 74% | 57% |
| Viral pneumonia | 78% | 63% |
| Aspiration pneumonia | 92% | 66% |
| Non-ARDS acute respiratory failure | 62% | 51% |
| Other | 65% | 52% |
Print
